GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
issued a press release announcing its preliminary financial
results for the fourth quarter and fiscal year ended December 31,
2016. A copy of the press release is attached hereto as Exhibit
99.1.
99.1, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or under the Securities Exchange Act of
1934, as amended, regardless of any general incorporation
language in any such filing, unless the Company expressly sets
forth in such filing that such information is to be considered
filed or incorporated by reference therein.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release dated January 10, 2017
|
About GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK)
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel. GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Recent Trading Information
GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) closed its last trading session 00.00 at 11.67 with 150,992 shares trading hands.